Business context and reporting period
Filing identity discrepancy: The request metadata names GYRE THERAPEUTICS, INC., but the filing is Catalyst Biosciences, Inc.’s Form 10-Q for the quarter ended June 30, 2019, filed August 1, 2019. Verify the issuer before relying on this summary.
Catalyst is a clinical-stage biopharmaceutical company developing engineered coagulation factors for hemophilia and other bleeding disorders. It had no approved products and had generated no product-sales revenue.
Financial performance and position
Amounts below are in millions of dollars except per-share data. Interim financial statements are unaudited.
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Contract revenue | $0 | $0 | $0 | $0.006 |
| Research and development expense | $11.1 | $3.9 | $23.1 | $7.7 |
| General and administrative expense | $3.3 | $3.2 | $7.0 | $6.1 |
| Net loss | $(13.8) | $(6.5) | $(28.9) | $(11.5) |
| Net loss per share | $(1.15) | $(0.54) | $(2.41) | $(1.10) |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $(26.4) | $(12.5) |
At June 30, 2019, cash and cash equivalents were $17.3 million and short-term investments were $76.6 million; together with restricted cash, total cash and investments were approximately $94.0 million. Total assets were $100.9 million, total liabilities $7.8 million, and stockholders’ equity $93.1 million. No conventional borrowings are disclosed; liabilities include operating lease obligations of $2.0 million. Gross margin and operating margin are not meaningful given the absence of material revenue.
Material changes versus prior comparable periods
- Q2 net loss more than doubled year over year, primarily as R&D expense increased 186% to $11.1 million, driven chiefly by clinical and manufacturing development of MarzAA and DalcA.
- Six-month R&D expense rose 202% to $23.1 million. Six-month operating cash use increased to $26.4 million from $12.5 million.
- Six-month 2018 other income included a $1.5 million milestone payment; its absence contributed to lower year-over-year interest and other income in 2019.
- Cash and investments declined from $120.1 million at December 31, 2018 to approximately $94.0 million at June 30, 2019. The 2019 period had no comparable equity financing; 2018 included $106.8 million in net proceeds from a public offering.
Outlook, commentary, and risks
- Management expected existing cash, cash equivalents, and short-term investments to fund requirements for at least 12 months from the filing date. It expected continuing losses and increasing expenses as development advances; it did not expect revenue for the remainder of 2019.
- MarzAA: The company reported completion of a Phase 2 open-label study with primary and secondary endpoints met. A July 8, 2019 update described a reduction in mean annualized bleed rate from 19.8 to 1.6 during treatment; a Phase 3 registration study was planned for 2020. A Phase 1 SC study was underway, with data expected in 2020.
- DalcA: A Phase 2b study was underway, with topline data expected in Q4 2019 and final data in 2020. Prior SC trial subjects developed neutralizing antibodies, which the company said did not prevent resumption of prior Factor IX therapy.
- Funding is not assured on acceptable terms. Potential responses to a shortfall include reduced or delayed R&D, additional financing, collaborations, licensing, or asset sales, each with potential costs such as dilution or relinquished rights.
- The company had $5.4 million of remaining payment obligations under $12.4 million in AGC manufacturing work orders. Agreements also provide for potential milestone payments of up to $17.5 million to Pfizer and up to $19.5 million to ISU Abxis, plus specified royalties.
- The company delayed further work on its Factor Xa program to focus on MarzAA and DalcA. No material legal proceedings were reported, and management said risk factors had not materially changed from the 2018 Form 10-K.
Important facts for investors to verify
- Confirm the issuer: this source is Catalyst Biosciences, not the company named in the request metadata.
- Check subsequent clinical, regulatory, and manufacturing updates against the stated MarzAA and DalcA milestones and timelines.
- Assess cash burn and runway against the company’s assumptions, planned R&D increases, and manufacturing commitments.
- Review potential financing needs, dilution risk, collaboration economics, milestone liabilities, and royalty terms.